Arvinas ARVN
NASDAQ ARVN
$7.72 +0.17 (+2.25%)
At close: Oct 22, 2026 · 4:00 PM EDT

Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018)

Updated

Arvinas (ARVN) reported Preferred Stock Liabilities of $630.33 million for Q3 2018, compared with $56.91 million a year earlier.

Analysis

Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends

At the end of FY2017, Arvinas posted Preferred Stock Liabilities of $61.48 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn -
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn -
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn -
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn -
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn -
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn -
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn -
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn -
10 Arvinas 504.12 Mn -2.15 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 630.33 Mn
Dec 31, 2017 61.48 Mn
Sep 30, 2017 56.91 Mn
API Access

Arvinas Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ARVN&period=max&api_key=YOUR_API_KEY